Scarica l'app Stockscreener
14.30
9.16%
1.20
Precedente Chiudi:
$13.10
Aprire:
$13.16
Volume 24 ore:
3.44M
Relative Volume:
0.95
Capitalizzazione di mercato:
$1.64B
Reddito:
$631.73M
Utile/perdita netta:
$-239.78M
Rapporto P/E:
-7.0792
EPS:
-2.02
Flusso di cassa netto:
$-33.45M
1 W Prestazione:
+7.04%
1M Prestazione:
+10.08%
6M Prestazione:
+31.19%
1 anno Prestazione:
-35.73%
Intervallo 1D:
$13.11
$14.30
Intervallo di 1 settimana:
$12.93
$14.30
Portata 52W:
$6.78
$24.76
10 X Genomics Inc Stock (TXG) Company Profile
Nome
10 X Genomics Inc
Settore
Industria
Telefono
(925) 401-7300
Indirizzo
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Confronta TXG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
14.30 | 1.68B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
290.86 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
80.52 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
67.74 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.82 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.24 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Iniziato | Leerink Partners | Outperform |
| 2024-07-22 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-07-18 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Downgrade | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-05-01 | Downgrade | TD Cowen | Buy → Hold |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-10 | Iniziato | Barclays | Overweight |
| 2023-03-31 | Iniziato | Stephens | Overweight |
| 2023-02-02 | Iniziato | UBS | Neutral |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-08-18 | Downgrade | Goldman | Neutral → Sell |
| 2022-07-25 | Iniziato | Canaccord Genuity | Buy |
| 2022-07-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-09-14 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-15 | Iniziato | William Blair | Outperform |
| 2020-12-02 | Iniziato | Goldman | Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-10 | Iniziato | Stifel | Buy |
| 2020-03-05 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-10-07 | Iniziato | BofA/Merrill | Buy |
| 2019-10-07 | Iniziato | Cowen | Outperform |
| 2019-10-07 | Iniziato | JP Morgan | Overweight |
| 2019-09-24 | Iniziato | Evercore ISI | Outperform |
Mostra tutto
10 X Genomics Inc Borsa (TXG) Ultime notizie
10x Genomics Launches Xenium Protein, Advancing Spatial Biology by Enabling Same-Cell RNA and Protein Analysis - BioSpace
Is 10x Genomics Inc. a play on infrastructure spendingEarnings Overview Summary & Long-Term Capital Growth Strategies - thegnnews.com
10x Genomics launches Xenium Protein for integrated RNA-protein analysis - Investing.com
First-Ever Single-Run RNA and Protein Analysis: 10x Genomics Revolutionizes Spatial Biology Research - Stock Titan
Quant Strategy Flags 10x Genomics Inc. for Entry2025 EndofYear Setup & Short-Term Trading Opportunity Alerts - newsyoung.net
10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery - ADVFN Brasil
Custom Dashboard Highlights 10x Genomics Inc. Price MomentumJuly 2025 Sector Moves & Daily Risk Controlled Trade Plans - beatles.ru
10x Genomics (TXG) Is Up 8.7% After Return to Profit and Tariff-Driven Sales Surge - simplywall.st
Cathie Wood's ARK buys Qualcomm and 10X Genomics stock - MSN
Analyzing 10x Genomics Inc. with multi timeframe chartsWeekly Market Outlook & Momentum Based Trading Ideas - Newser
Relative strength of 10x Genomics Inc. in sector analysisJuly 2025 Spike Watch & Community Consensus Trade Signals - Newser
What to do if you’re stuck in 10x Genomics Inc.July 2025 Price Swings & High Return Trade Guides - Newser
Real time alert setup for 10x Genomics Inc. performanceQuarterly Profit Summary & AI Enhanced Trading Signals - Newser
Can 10x Genomics Inc. stock double in the next yearSwing Trade & Smart Investment Allocation Insights - sundaytimes.kr
Market reaction to 10x Genomics Inc.’s recent newsWeekly Investment Report & Weekly Watchlist for Hot Stocks - Newser
Is 10x Genomics Inc. a potential multi baggerGap Down & Real-Time Volume Surge Alerts - newsyoung.net
10x Genomics’ (TXG) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
What makes 10x Genomics Inc. stock price move sharplyPortfolio Performance Report & Free Accurate Trade Setup Notifications - Newser
Building trade automation scripts for 10x Genomics Inc.Trade Volume Summary & Free Growth Oriented Trading Recommendations - Newser
10x Genomics Reports Second Quarter 2025 Financial Results - ADVFN Brasil
10x Genomics Reports First Quarter 2025 Financial Results - ADVFN Brasil
10x Genomics to Acquire Scale Biosciences - SynBioBeta
Brookdale, Evolent Health, Fortrea, 10x Genomics, and Organon Stocks Trade Up, What You Need To Know - Yahoo Finance
10X Genomics’ SWOT analysis: genomics firm’s stock faces funding headwinds By Investing.com - Investing.com Nigeria
10X Genomics’ SWOT analysis: genomics firm’s stock faces funding headwinds - Investing.com
Earnings Beat: 10x Genomics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
10x Genomics (NASDAQ:TXG) Given New $17.00 Price Target at Morgan Stanley - Defense World
10X Genomics Q2 Earnings Call Highlights: Balancing Growth and Challenges with Strong China Performance and Favorable Bruker Settlement - AInvest
10x Genomics (NASDAQ:TXG) Given Consensus Rating of “Hold” by Brokerages - Defense World
Price Floor Holding on 10x Genomics Inc. — Rebound PossibleBuy Alerts With Low Risk Confirmation Noted - sundaytimes.kr
10X Genomics Balances Growth and Challenges in Earnings Call - TipRanks
Does 10x Genomics Inc. qualify in momentum factor screeningEntry Zone Watchlist With Momentum Focus - Newser
Tandem Diabetes, iRhythm, agilon health, Fortrea, and 10x Genomics Shares Skyrocket and Plummet, What You Need To Know - Yahoo Finance
Does 10x Genomics Inc. offer margin of safetyFree Weekly Earnings Watchlist - thegnnews.com
10x Genomics, Inc. (NASDAQ:TXG) Q2 2025 Earnings Call Transcript - Insider Monkey
Zacks.com featured highlights include Tsakos Energy Navigation Limited, 10x Genomics, Pan American Silver, Wolverine World Wide and Interface - Yahoo Finance
Will Breakout in 10x Genomics Inc. Sustain Through Next WeekIntraday Trend Analysis for Fast Gains Released - beatles.ru
Is 10x Genomics Inc. stock reversal real or fakeForecasting Stock Moves with AI Insights - Newser
10x Genomics (NASDAQ:TXG) Receives “Overweight” Rating from Barclays - Defense World
Chart Analysts Warn of Resistance Near 10x Genomics Inc. PriceDaily Smart Money Movement Monitor Activated - beatles.ru
10x Genomics Sees Strong Growth with Q2 Results, Strategic Acquisition, and Optimistic Outlook - AInvest
Transcript : 10x Genomics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
10x Genomics (NASDAQ:TXG) Shares Gap Up on Better-Than-Expected Earnings - Defense World
10x Genomics (NASDAQ:TXG) Upgraded to Buy at Wall Street Zen - Defense World
Why 10x Genomics (TXG) Is Down 6.0% After Tariff-Driven Q2 Revenue Surge and Guidance Update - simplywall.st
10x Genomics shares rise 1.71% after-hours following Q2 revenue beat and Deutsche Bank price target adjustment. - AInvest
10x Genomics: UBS maintains a 'Neutral' Rating, The Target Price is $13 - AInvest
10x Genomics: UBS maintains Neutral rating, raises PT to $13 from $12. - AInvest
10x Genomics shares fall 4.65% intraday after reporting Q2 revenue of $172.9M, below analyst estimates of $139.4M. - AInvest
10x Genomics (NASDAQ:TXG Shareholders Incur Further Losses as Stock Declines 4.8% This Week, Taking Five-year Losses to 88% - 富途牛牛
Why 10x Genomics (TXG) Stock Is Falling Today - Yahoo Finance
10 X Genomics Inc Azioni (TXG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.72%
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):